EAEU Hits Hurdles In Implementing New Pharma, Medical Product Regulations
This article was originally published in SRA
Executive Summary
Pharmaceutical and medical product companies operating in countries of the Eurasian Economic Union (EAEU) will soon be facing a new set of regulations that among other things are intended to establish a single EAEU market with free movement of medicines and medical goods, introduce a new decentralized drug approvals procedure, and help bring down pharmaceutical prices through greater competition.